Market closedNon-fractional
Puma Biotechnology/PBYI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Ticker
PBYI
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Los Angeles, United States
Employees
185
Website
www.pumabiotechnology.com
PBYI Metrics
BasicAdvanced
$142M
Market cap
9.30
P/E ratio
$0.32
EPS
1.30
Beta
-
Dividend rate
Price and volume
Market cap
$142M
Beta
1.3
Financial strength
Current ratio
1.457
Quick ratio
1.342
Long term debt to equity
118.53
Total debt to equity
217.204
Interest coverage (TTM)
1.98%
Management effectiveness
Return on assets (TTM)
8.10%
Return on equity (TTM)
40.02%
Valuation
Price to earnings (TTM)
9.301
Price to revenue (TTM)
0.619
Price to book
2.8
Price to tangible book (TTM)
-19.18
Price to free cash flow (TTM)
6.091
Growth
Revenue change (TTM)
-3.59%
Earnings per share change (TTM)
205.50%
3-year revenue growth
-5.91%
3-year earnings per share growth
-22.28%
What the Analysts think about PBYI
Analyst Ratings
Majority rating from 3 analysts.
PBYI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$44M
-39.39%
Net income
-$4.8M
-139.34%
Profit margin
-10.98%
-164.89%
PBYI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.05
$0.12
$0.26
-$0.10
-
Expected
$0.01
$0.08
$0.30
-$0.22
-$0.10
Surprise
566.67%
56.52%
-13.24%
-53.85%
-
PBYI News
AllArticlesVideos
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
Business Wire·1 month ago
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Puma Biotechnology stock?
Puma Biotechnology (PBYI) has a market cap of $142M as of July 06, 2024.
What is the P/E ratio for Puma Biotechnology stock?
The price to earnings (P/E) ratio for Puma Biotechnology (PBYI) stock is 9.3 as of July 06, 2024.
Does Puma Biotechnology stock pay dividends?
No, Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Puma Biotechnology dividend payment date?
Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders.
What is the beta indicator for Puma Biotechnology?
Puma Biotechnology (PBYI) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Puma Biotechnology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.